TET2 is an enzyme for converting methylcytosine (mC) to hydorxymethylcytosine (hmC) and its mutations have been frequently found in myeloid malignancies and T-cell lymphoma in humans. We analyzed Tet2 gene trap mice and found that homozygous mice developed T-cell lymphoma with follicular helper T-cell-like features.
Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice.
Specimen part
View SamplesThis SuperSeries is composed of the SubSeries listed below.
Frequent pathway mutations of splicing machinery in myelodysplasia.
Cell line
View SamplesIn this study, to obtain the biological impact of the mutated U2AF35, HeLa and TF-1 cells were retrovirally transduced with either mock, wild-type or S34F mutant of U2AF35, and Expression array was performed.
Frequent pathway mutations of splicing machinery in myelodysplasia.
Cell line
View SamplesIn this study, to obtain the biological impact of the mutated U2AF35, HeLa cells were retrovirally transduced with either mock, wild-type or S34F mutant of U2AF35, and Exon array was performed.
Frequent pathway mutations of splicing machinery in myelodysplasia.
Cell line
View SamplesComparison of mRNA expression from FACS isolated Gli1 expressing stromal cells from mice given SAG21k versus vehicle
Control of inflammation by stromal Hedgehog pathway activation restrains colitis.
Sex, Specimen part, Treatment
View SamplesComparative analysis of mRNA from colons of mice that were given colitis though use of 5% dextran sulfate in the drinking water (Days 0-5)
Control of inflammation by stromal Hedgehog pathway activation restrains colitis.
Sex, Specimen part, Treatment
View SamplesThis SuperSeries is composed of the SubSeries listed below.
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Specimen part, Disease, Cell line
View SamplesWe recently identified recurrent mutations of cohesin complex in myeloid neoplasms through whole-exome sequencing analysis. RAD21 is one of the main components of the cohesin complex.
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Cell line
View SamplesThis SuperSeries is composed of the SubSeries listed below.
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
Specimen part, Disease, Disease stage, Cell line
View SamplesBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare skin-tropic hematological malignancy of uncertain pathogenesis and poor prognosis. We examined 118 BPDCN cases for cytomorphology, MYC locus rearrangement, and MYC expression. Sixty-two (53%) and 41 (35%) showed the classic and immunoblastoid cytomorphology, respectively. Forty-one (38%) MYC+BPDCN (positive for rearrangement and expression) and 59 (54%) MYC-BPDCN (both negative) cases were identified. Immunoblastoid cytomorphology was significantly associated with MYC+BPDCN. All examined MYC+BPDCNs were negative for MYB/MYBL1 rearrangement (0/36). Clinically, MYC+BPDCN showed older onset, poorer outcome, and localized skin tumors more commonly than MYC-BPDCN. MYC was demonstrated by expression profiling as one of the clearest discriminators between CAL-1 (MYC+BPDCN) and PMDC05 (MYC-BPDCN) cell lines, and its shRNA knockdown suppressed CAL-1 viability. Inhibitors for bromodomain and extraterminal protein (BETis) and aurora kinases (AKis) inhibited CAL-1 growth more effectively than PMDC05. We further showed that a BCL2 inhibitor was effective in both CAL-1 and PMDC05, indicating that this inhibitor can be used to treat MYC-BPDCN, to which BETis and AKis are probably less effective. Our data will provide a rationale for the development of new treatment strategies for patients with BPDCN in accordance with precision medicine.
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
Specimen part, Disease, Disease stage, Cell line
View Samples